ATXI

Avenue Therapeutics, Inc.

3.34 USD
-0.12 (-3.47%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Avenue Therapeutics, Inc. stock is down -0.6% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 12.5% of the previous 7 July’s closed higher than June.

About Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.